References

1. Elias M, Pievani D, Randoux C, et al. COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes. J Am Soc Nephrol. 2020;31(10):2413-2423.
2. Cravedi P, Mothi SS, Azzi Y, et al. COVID‐19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140-3148.
3. Abolghasemi S, Mardani M, Sali S, Honarvar N, Baziboroun M. COVID‐19 and kidney transplant recipients. Transpl Infect Dis. 2020;22(6):e13413.
4. Sran K, Olsburgh J, Kasimatis T, et al. COVID-19 in Kidney Transplant Patients from a Large UK Transplant Centre: Exploring Risk Factors for Disease Severity. Transplant Proc. 2020;S0041-1345(20)32901-8.
5. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973-1983.
6. De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2021;32(2):385-396.
7. Burack D, Pereira MR, Tsapepas DS, et al. Prevalence and Predictors of SARS‐CoV‐2 Antibodies among Solid Organ Transplant Recipients with Confirmed Infection. Am J Transplant. 2021;10.1111/ajt.16541.
8. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-848.
9. Azzi Y, Parides M, Alani O, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 2020;98(6):1559-1567.
10. Alkurt G, Murt A, Aydin Z, et al. Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey. PloS One. 2021;16(3):e0247865.
11. Prendecki M, Clarke C, McKinnon T, et al. SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. Kidney Med. 2021;3(1):54-59. e1.
12. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778-785.
13. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204.
14. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027-2034.
15. Gandhi R, Lynch J, Del Rio C. Mild or moderate COVID-19 [published online ahead of print, 2020 Apr 24]. N Engl J Med. 2020;383(18):1757-1766.
16. Trabulus S, Karaca C, Balkan II, et al. Kidney function on admission predicts in-hospital mortality in COVID-19. Plos One. 2020;15(9):e0238680.
17. Hartzell S, Bin S, Benedetti C, et al. Evidence of potent humoral immune activity in COVID‐19‐infected kidney transplant recipients. Am J Transplant. 2020;20(11):3149-3161.
18. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-1199.
19. Petrilli C, Jones S, Yang J. Factors associated with hospitalisation and critical illness among 5279 patients with coronavirus disease 2019 in New York city prospective cohort study. BMJ. 2020;369:m1966.
20. Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. PloS One. 2020;15(7):e0236240.
21. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.
22. Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270-e2012270.
23. Helvaci N, Eyupoglu ND, Karabulut E, Yildiz BO. Prevalence of obesity and its impact on outcome in patients with COVID-19: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:598249.
24. Stout RL, Rigatti SJ. Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020. JAMA Netw Open. 2021;4(3):e211552-e211552.
25. Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12(559):eabc3103.
26. Benotmane I, Gautier Vargas G, Velay A, et al. Persistence of SARS‐CoV‐2 antibodies in kidney transplant recipients. Am J Transplant. 2020; 10.1111/ajt.16469.
Table 1 . Demographic, clinical, and laboratory parameters of kidney transplant recipients grouped according to COVID-19 status.